What happens if you stop CPAP: timeline of consequences and re-starting after a gap

Patients who have been on CPAP for months or years eventually ask some version of the same question: “What happens if I just stop?” The short answer, from the experimental and observational data, is that the consequences unfold on two very different timescales. Symptoms return within days. Surrogate cardiovascular markers deteriorate within weeks. Actual event risk — stroke, heart attack, arrhythmia — accrues over years of accumulated untreated apnea exposure. This article sets out the timeline, what the CPAP-withdrawal trials actually showed, and the practical guidance for patients who have been off therapy and want to restart.

Days 1–7 — symptoms return

OSA is not cured by CPAP. It is treated, mechanically, each night. The moment the pressure stops, the underlying airway anatomy and physiology are exactly what they were before CPAP ever started. In a patient with moderate-to-severe OSA, the clinical picture returns rapidly:

• Night 1. Snoring resumes immediately. Bed-partner-observed apneas return. Sleep fragmentation — micro-arousals at every apnea termination — returns. The patient has one bad night.
• Nights 2–4. Daytime sleepiness climbs back toward pre-CPAP baseline. The patient who was driving safely on CPAP is measurably less alert. Reaction times on simulator tasks deteriorate within 3–5 nights to something approaching the pre-treatment impairment level. .
• Nights 5–7. Morning headache, especially in OHS or hypercapnic overlap patients. Concentration and mood deterioration reported by family members. Nocturnal polyuria — the nocturnal-diuresis effect of apnea-induced hypoxia — returns.

The patient’s subjective experience is often: “I didn’t realise how much better I felt until I stopped.” That is the clinical signal — therapy that was invisible while working becomes conspicuous in its absence.

Weeks 1–2 — physiological markers deteriorate

The CPAP-withdrawal trials are the gold-standard evidence for what happens in the weeks after stopping. Investigators enrolled well-adherent OSA patients, randomised half to stop CPAP (usually with a sham low-pressure device to maintain blinding) and half to continue, and measured outcomes at 2 weeks.

The findings, across multiple trials:

• AHI returns to pre-treatment baseline within 1–3 nights. No gradual return — the apneas are back from night 1.
• Daytime blood pressure rises by 3–5 mmHg systolic within 2 weeks. Ambulatory BP monitoring shows the effect is largest in the early-morning hours. .
• Endothelial function, measured as flow-mediated dilation, deteriorates within 2 weeks. The vascular biology returns to an untreated-OSA state.
• Heart-rate variability patterns shift toward sympathetic predominance within 1 week.
• Insulin sensitivity worsens in patients with diabetes or pre-diabetes within 2 weeks. Morning fasting glucose climbs by a small but measurable amount.
• C-reactive protein and inflammatory markers rise.

The 2-week timeline is consistent across studies. The biology is not hibernating; it is running untreated as soon as the pressure is off.

Months — cardiovascular risk accrues

The longer-term picture comes from observational cohorts comparing CPAP-adherent OSA patients against CPAP-abandoning OSA patients matched for baseline severity. The effect sizes, over 5–10 years of follow-up:

• Hypertension prevalence is higher in CPAP-abandoning OSA patients than in adherent OSA patients; medication requirements climb.
• Incident atrial fibrillation risk is elevated 2-fold in untreated severe OSA compared to treated.
• Ischaemic stroke incidence is elevated roughly 2-fold in severe OSA, attenuated by adherent CPAP use. .
• Cardiovascular mortality is elevated in severe untreated OSA, with the magnitude depending on coexisting conditions.
• Diabetes control worsens. HbA1c in the diabetic-OSA overlap population climbs by 0.2–0.4% points when CPAP is discontinued. .

The risk accrual is not linear. A patient who stops CPAP for 6 weeks and restarts has accumulated a modest exposure. A patient who stops for 3 years has a materially higher event risk, and much of that risk does not “catch up” when therapy is resumed — the underlying vascular damage from chronic nocturnal hypoxia does not fully reverse.

The specific case of diabetic OSA overlap

OSA and type 2 diabetes co-occur frequently. The mechanisms cross-fertilise: nocturnal hypoxia worsens insulin resistance; obesity drives both conditions; sleep fragmentation increases hepatic glucose output; sympathetic surge during apneas disrupts overnight glucose homeostasis.

When a diabetic OSA patient stops CPAP, glucose control deteriorates within 2 weeks. HbA1c trends up at the next quarterly check. The patient, and often the prescribing physician, attributes the deterioration to diet, stress, or medication adjustment — missing the CPAP abandonment as the actual driver. For diabetic patients, CPAP adherence is more than sleep-quality optimisation; it is part of glycaemic management. .

Why patients stop — the driver is usually addressable

Most CPAP abandonment is not a considered clinical decision. It is an accumulation of small frictions: mask leak overnight, rainout in the hose, pressure feels uncomfortable, cold away from home, loud for the partner. The patient takes a “one-night break”, the break becomes a week, and the device ends up in a cupboard.

Abandonment driven by tolerable, fixable friction is the category that responds to intervention — a mask change, pressure adjustment, humidifier refit, heated tube addition. Abandonment driven by a genuine therapy intolerance is a smaller category and warrants a different conversation — alternative therapy (mandibular advancement device, positional therapy, upper-airway surgery, hypoglossal nerve stimulation where available).

Before concluding that CPAP does not work, the patient and physician should confirm that the last 30 days of use have been on optimal settings with a download-reviewed residual AHI below 5 and leak within acceptable thresholds. Abandoning suboptimal CPAP is not the same decision as abandoning optimised CPAP.

Restarting after a gap

Patients who have stopped CPAP and want to restart are the other common clinical scenario. The practical guidance depends on how long the gap has been:

• Less than 1 month off therapy. Restart on the last prescribed settings. Pressure tolerance is likely unchanged. Check the mask and tubing for wear; replace the mask cushion if it has been sitting unwashed. Review download data at 2 weeks.
• 1–3 months off therapy. Restart on last prescribed settings, but expect the patient to feel the pressure more acutely than they remember. Use the ramp-up feature (pressure starts low and climbs over 15–45 minutes). Review download data at 2 weeks; mild downward adjustment of pressure may be needed for tolerability.
• More than 3 months off therapy. Re-titration is recommended. Body weight may have changed (often up), positional preference may have shifted, comorbidities (hypertension medications, diabetes) may have evolved. A fresh sleep study or at minimum a weeklong download-review on APAP is appropriate to confirm therapeutic pressure range.
• More than 12 months off therapy. Full re-evaluation. A fresh polysomnography or home sleep study is warranted because OSA severity may have changed materially. Do not assume the 2021 titration numbers still apply in 2026.

In all cases, inspect the device. Humidifier chambers scaled with hard-water deposits do not humidify correctly. Mask cushions more than 6 months unused degrade. Heated tube elements may have failed if stored in damp conditions. Filters should be replaced before restart.

The “CPAP vacation” conversation

Patients sometimes request a scheduled break — a vacation week, a business trip, a short hospital admission. The clinical response depends on context. For a well-controlled non-hypoxic OSA patient, missing 2–3 nights is usually unremarkable. For a severe OSA patient with significant desaturations and known cardiovascular disease, even a single night off therapy is not trivial — the morning BP spike and the REM-sleep hypoxaemia are real. For the hospitalised surgical patient in particular, OSA unmasked by postoperative opioids is a known peri-operative risk and CPAP should be continued in hospital wherever possible.

The answer to “can I skip CPAP for a week” is rarely a categorical yes or no; it depends on severity and comorbidity, and it is a conversation for the prescribing physician, not an informal decision.

Pregnancy-specific considerations

Women diagnosed with OSA during pregnancy who stop CPAP before delivery or during post-partum can accumulate cardiovascular exposure at a point where pre-eclampsia, gestational hypertension, and gestational diabetes are all significantly modulated by nocturnal oxygenation. Pregnancy-related weight gain and fluid redistribution can also worsen OSA severity from baseline to third trimester, so a patient who was on appropriate CPAP pre-pregnancy and stops during pregnancy may be worse off than the diagnostic numbers suggest. Indian obstetric-sleep practice is relatively under-developed, and this patient population is under-served. Pregnant OSA patients on CPAP should generally continue therapy throughout pregnancy; abandonment is not a benign decision in this group. .

Peri-operative CPAP

Patients on CPAP who stop before an elective surgery — because they were not sure whether to bring the device, because the hospital pre-admission instructions did not cover it, or because they assumed it was irrelevant — are at elevated risk of post-operative respiratory complications, particularly if the surgery involves general anaesthesia, opioids, or supine recovery. Unmasked OSA combined with residual anaesthetic and opioid respiratory depression is a recognised cause of peri-operative arrest.

Indian surgical centres increasingly ask about CPAP use during pre-admission assessment, but coverage is not universal. Patients on CPAP undergoing any surgical procedure — including minor day-case procedures — should bring their device, confirm with the anaesthetist whether it will be used in recovery, and ensure continuation at home from post-op night 1. The risk is not hypothetical; it is a well-documented morbidity pattern. .

Self-assessment after a CPAP gap

A patient restarting CPAP after a gap can gauge whether re-titration is needed using several self-observable markers:

• Pressure tolerability. Does the prescribed pressure feel harder to tolerate than before? If so, re-titration is advisable.
• Mask comfort. Has weight changed, facial contour changed (edentulism, dentures), or skin tone changed? A previously well-fitting mask may no longer fit.
• Residual symptoms on therapy. Does the patient still feel sleepy, wake unrefreshed, or have morning headaches after 2 weeks of consistent use? Indicates suboptimal therapy and a re-evaluation is warranted.
• Download-data residual AHI. If the device reports residual AHI above 5 on the restarted settings, the therapy is not optimal.
• Partner reports. Does the bed-partner notice snoring, gasping, or breath-holding on therapy? A “yes” indicates inadequate pressure.

Any of these findings after restart should prompt contact with a sleep physician, not continued tolerance of a suboptimal therapy.

Social and behavioural dimensions

Abandonment often has non-clinical drivers that the medical literature under-represents:

• Travel logistics. A patient who struggled with CPAP on an international flight abandons the device during the trip, then struggles to resume on return. The solution is a travel CPAP (ResMed AirMini, BMC M1 Mini, Breas Z2) or at minimum practised travel with the primary device.
• Partner dynamics. A new partner who finds CPAP objectionable, a partner’s health event that disrupts routine, a separation that changes sleeping arrangements — all documented abandonment triggers.
• Economic disruption. Job loss, relocation to a city without dealer support, shift work making consistent sleep hard — all reduce CPAP use.
• Device failure. The patient whose machine breaks down and who does not immediately replace it often never returns to therapy. Hold a backup plan: know the replacement process, have warranty information accessible.

These are not clinical problems in the narrow sense, but they are the main drivers of real-world abandonment after the first-year window has been successfully crossed. Sleep physicians who address them in routine follow-up see better long-term adherence than those who focus exclusively on the physiology.

Takeaway

Stopping CPAP produces measurable physiological deterioration within days and accruing cardiovascular risk within years. The withdrawal trials establish that the biology returns to untreated-OSA baseline within 2 weeks — there is no gradual “wash-out protection”. Restart after a gap of more than 3 months should include fresh titration; after a gap of more than 12 months, re-evaluation from the diagnostic sleep study onward is appropriate.

Patients considering a CPAP break for tolerability reasons should first rule out whether the tolerability problem is addressable with mask, pressure, or humidification adjustment. Patients considering a break for clinical reasons — “I feel fine, I don’t think I need it” — should discuss this with their sleep physician before abandoning therapy, because the subjective absence of sleepiness does not mean the underlying vascular and metabolic costs have gone away. .